U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~May 31~~November 30, 2018

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File No. 333-154989

	ENTEST GROUP, INC.
	(Exact name of small business issuer as specified in its charter)

Nevada	26-3431263
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

~~4700~~No. ~~Spring~~911 ~~Street, St 304, La Mesa, California 91942 (Address of Principal Executive Offices) (619)-702-1404 (Issuer~~Bao’san ~~telephone~~Book ~~number) ENTEST BIOMEDICAL, INC. (Former name, address and fiscal year, if changed since last report)~~City

~~Check whether~~XInqiao ~~the~~Street ~~issuer~~Central ~~(1)~~Road, ~~has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding~~Bao’an 12District, ~~months (or for such shorter period that the issuer was required to file such reports)~~Shenzhen, ~~and (2) has been subject to such filing requirements for the past 90 days.~~China

~~Yes ☒ No ☐~~(Address of Principal Executive Offices) 86 -13709631109 (Issuer’s telephone number) ENTEST BIOMEDICAL, INC. (Former name, address and fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has ~~submitted~~filed ~~electronically~~all ~~and~~reports ~~posted on its corporate Web site, if any, every Interactive Data File~~ required to be ~~submitted~~filed ~~and~~by ~~posted~~Section ~~pursuant~~13 toor ~~Rule~~15(d) ~~405~~ of ~~Regulation~~the ~~S-T~~Securities (§Exchange ~~232.405~~Act of ~~this~~1934 ~~chapter)~~ during the ~~preceding~~ preceding 12 months (or for such shorter period that the registrant was required to ~~submit~~file such reports), and ~~post~~(2) has been subject to such filing ~~files)~~requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “~~non-accelerated~~smaller reporting ~~filer,~~company” and “~~smaller~~emerging ~~reporting~~growth company” in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒☐ Smaller reporting company ☒ Emerging growth company ☐

~~APPLICABLE~~If an emerging growth company, indicate ~~ONLY~~by TOcheck ~~CORPORATE~~mark ~~ISSUERS:~~ if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

AsIndicate by check mark whether the registrant ofis ~~May~~a ~~31,~~shell ~~2018~~company ~~there~~(as ~~were~~defined ~~49,170,472~~in ~~shares~~Rule 12b-2 of ~~common~~the ~~stock~~Exchange ~~issued~~Act). ~~and~~Yes ~~outstanding.~~☒ No ☐

~~Indicate by~~As ~~check~~of ~~mark~~January ~~whether~~18, ~~the~~2018, ~~registrant~~there iswere a49,170,472 shares ~~shell~~of ~~company~~common ~~(as~~stock ~~defined~~issued inand ~~Rule 12b-2 of the Exchange Act):~~outstanding.

~~Yes ☐ No ☒~~TABLE OF CONTENTS

Transitional Small Business Disclosure Format (Check One)

		Page
PART I – FINANCIAL INFORMATION:
Item 1.	Financial Statements:
	Condensed Balance Sheets as of November 30, 2018 (Unaudited) and August 31, 2018	3
	Condensed Statements of Operations for the Three Months Ended November 30, 2018 and November 30, 2017 (Unaudited)	4
	Condensed Statement of Cash Flows for the Three Months Ended November 30, 2018 and November 30, 2017 (Unaudited)	6
	Notes to Condensed Financial Statements (Unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	20

PART II – OTHER INFORMATION:
Item 1.	Legal Proceedings	20
Item 1A.	Risk Factors	20
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3.	Defaults Upon Senior Securities	20
Item 4.	Mine Safety Disclosures	20
Item 5.	Other Information	20
Item 6.	Exhibits	21

Yes ☐ No ☒

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ENTEST GROUP,INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Balance Sheet
	As of
	May 31, 2018 (Unaudited)			August 31, 2017
ASSETS
Current Assets
Cash		423,974			86,559
Accrued Interest Receivable		1,040			908
Current Portion of Prepaid Expenses		108,041			58,652
Accrued Rent Receivable		0			0
Total Current Assets		533,055			146,119
OTHER ASSETS
Available for Sale Securities		77,700			190,050
Long Term Portion Prepaid Expenses		68,000
TOTAL ASSETS		678,755			336,169
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts Payable		332,940			28,446
Notes Payable		16,501			13,501
Due to Other		8,000			8,000
Unearned Rental Income		20,000
Property Dividend Payable		57,143
Accrued Expenses		183,755			269,398
Total Current Liabilities		618,339			319,345
TOTAL LIABILITIES		618,339			319,345
STOCKHOLDERS' EQUITY
Common Stock, authorized 500,000,000 shares as of August 31, 2017 and May 31, 2018; issued and outstanding 46,670,472(par value $0.0001) as of August 31, 2017 and 49,170,472 as of May 31, 2018		4,911			4,661
Preferred Stock ,par value $0.0001 5,000,000 shares authorized,
Series AA Preferred Stock, 100,000 shares authorized, 634 shares, par value $0.0001, issued and outstanding at August 31, 2017 and as of May 31, 2018		0			0
Series B Preferred 4,400,000 shares authorized, 728,073 ( par value $0.0001) issued and outstanding as of May 31, 2018 and 728,073 issued and outstanding as of August 31, 2017		73			73
Series AAA Preferred, 300,000 shares authorized, $0.0001 par value 534 shares outstanding as of May 31, 2018 and as of August 31, 2017		0			0
NonVoting Convertible Preferred ($1 par value) 3,000,000 shares authorized as of May 31, 2018 and August 31, 2017 respectively, 1,001,533 and 1,026,533 issued and outstanding as of May 31, 2018 and August 31, 2017, respectively		1,001,533			1,026,533
Additional Paid in Capital		8,562,414			7,191,000
Contributed Capital		274,662			274,662
Accumulated Deficit		(9,965,556	)		(8,721,498	)
Accumulated Other Comprehensive Income		72,700			185,050
Total Stockholders' Equity Entest Biomedical, Inc.		(49,263	)		(39,519	)
Non Controlling Interest Zander Therapeutics Inc.		109,679			56,343
Stockholders Equity		60,416			16,824
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY		678,755			336,169
The accompanying Notes are an integral part of these Financial Statements

ENTEST GROUP,INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Statement of Operations
(unaudited)
	Three Months Ended						Nine Months Ended
	May 31, 2018			May 31, 2017			May 31, 2018			May 31, 2017
TOTAL REVENUE		0			0			0			0
COSTS AND EXPENSES
Research and Development		459,584			12,020			749,584			14,520
Rent Costs		9,348			8,988			27,684			28,494
General and Administrative		83,727			44,655			164,583			180,859
Consultant's Expenses		80,980			36,038			289,170			188,945
Total Costs and Expenses		633,639			101,701			1,231,021			412,818
OPERATING LOSS		(633,639	)		(101,701	)		(1,231,021	)		(412,818	)
OTHER INCOME AND EXPENSE
Rental income		15,000			15,000			45,000			45,000
Interest Income		0			789			132			789
Other Income		0			11,605						76,697
Loss on Issuance of Stock Below Fair Value		0									(107,700	)
Interest Expense		(361	)		(15,882	)		(1,025	)		(42,662	)
TOTAL OTHER INCOME AND EXPENSE		14,639			11,512			44,107			(27,876	)
LOSS BEFORE INCOME TAXES		(619,000	)		(90,189	)		(1,186,914	)		(440,694	)
Income Taxes		0			0			0			0
NET LOSS
NET LOSS from continuing operations		(619,000	)		(90,189	)		(1,186,914	)		(440,694	)
Less: (Net Income) Loss attributable to non controlling interest in Zander Therapeutics, Inc.		249,372			68			467,204			68
NET LOSS available to common shareholders		(369,628	)		(90,121	)		(719,710	)		(440,626	)
BASIC AND DILUTED EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS		(0.008	)		(0.002	)		(0.015	)		(0.011	)
WEIGHTED AVERAGE NUMBER COMMON SHARES OUTSTANDING		49,170,472			40,739,703			49,106,134			41,630,766
The accompanying Notes are an integral part of these Financial Statements

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

ENTEST GROUP,INC.

(Formerly called ENTEST BIOMEDICAL, INC.)

Consolidated Balance Sheet

	As of November 30, 2018 (unaudited)			As of August 31, 2018

ASSETS
Current Assets
Cash		149			267
Accrued Interest Receivable		1,040			1,040
Current Portion of Prepaid Expenses					8,000
Accrued Rent Receivable					0

Total Current Assets		1,189			9,307

OTHER ASSETS
Available for Sale Securities		0			0
Long Term Portion Prepaid Expenses		0			0

TOTAL ASSETS		1,189			9,307

LIABILITES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts Payable		2,387			28,447
Notes Payable		0			19,601
Due to Other					8,000
Unearned Rental Income		0			17,000
Bank Overdraft		0			66
Property Dividend Payable
Accrued Expenses		3,080			181,904
Total Current Liabilities		5,467			255,018

TOTAL LIABILITIES		5,467			255,018

STOCKHOLDERS’ EQUITY
Common Stock, authorized 500,000,000 shares as of November 30, 2018 and August 31, 2018; issued and outstanding 49,170,472(par value $0.0001) as of November 30, 2018 and 49,170,472 as of August 31, 2018		4,911			4,911
Preferred Stock, par value $0.0001 5,000,000 shares authorized,

Series AA Preferred Stock, 100,000 shares authorized, 667 shares, par value $0.0001, issued and outstanding at November 30, 2018 and as of August 31, 2018		0			0
Series B Preferred 4,400,000 shares authorized, 728,009 ( par value $0.0001) issued and outstanding as of August 31, 2018 and 728,009 issued and outstanding as of November 30, 2018		73			73

Series AAA Preferred, 300,000 shares authorized, $0.0001 par value 534 shares outstanding as of August 31, 2018 and as of November 30, 2018		0			0
NonVoting Convertible Preferred ($1 par value) 3,000,000 shares authorized as of August 31, 2018 and November 30, 2018, respectively, 1,001,533 issued and outstanding as of August 31, 2018 and November 30,2018		1,001,533			1,001,533
Additional Paid in Capital		8,729,236			8,729,236
Contributed Capital		296,084			274,662
Accumulated Deficit		(10,036,115	)		(10,256,126	)
Accumulated Other Comprehensive Income					0
Total Stockholders’ Equity Entest Biomedical, Inc.		(4,278	)		(245,711	)
Non Controlling Interest Zander Therapeutics Inc.					0
Stockholders’ Equity		(4,278	)		(245,711	)

TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY		1,189			9,307

The accompanying Notes are an integral part of these Financial Statements

ENTEST GROUP,INC.
(formerly known as ENTEST BIOMEDICAL , INC.)
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited)
	Three Months Ended May 31,
	2018			2017
Net Income (Loss)	$	(619,000	)	$	(90,189	)
Add:
Unrealized Gains on Securities		0
Less:
Unrealized Losses on Securities		(65,800	)		(92,050	)
Comprehensive Income attributable to Non Controlling Interest		0			0
Total Other Comprehensive Income (Loss)		(65,800	)		(92,050	)
Comprehensive Income	$	(684,800	)	$	(182,239	)
		Nine Months Ended May 31,
		2018			2017
Net Income (Loss)	$	(1,186,914	)	$	(440,694	)
Add:
Unrealized Gains on Securities		43,750			223,500	)
Less:
Unrealized Losses on Securities		(156,100	)		(92,050	)
Comprehensive Income attributable to Non Controlling Interest		0
Total Other Comprehensive Income (Loss)		(112,350	)		131,450
Comprehensive Income	$	(1,299,264	)	$	(309,244	)
The accompanying Notes are an integral part of these Financial Statements

ENTEST GROUP, INC.

(Formerly called ENTEST BIOMEDICAL, INC.)

Consolidated Statement of Operations

(unaudited)

	Quarter Ended November 30, 2018			Quarter Ended November 30, 2017
TOTAL REVENUE		0			0


COSTS AND EXPENSES
Research and Development		0			0
Rent Costs		4,912			8,988
General and Administrative		6,703			39,685
Consultant’s Expenses		2,439			124,099
Total Costs and Expenses		14,054			172,772

OPERATING LOSS		(14,054	)		(172,772	)

OTHER INCOME AND EXPENSE
Rental income		28,000			15,000
Interest Income
Gain on Write Off of Accounts Payable		23,629
Loss on Issuance of Stock Below Fair Value
Gain on Disposition of Zander		188,589
Equity in Losses of Zander
Gain on Sale of Securities
Refund on Amount Previously Paid		1,289
Loss on Disposition of Entest Biomedical		(6,947	)
Interest Expense		(495	)		(334	)

TOTAL OTHER INCOME AND EXPENSE		234,065			14,666

INCOME (LOSS )BEFORE INCOME TAXES		220,011			(158,106	)
Income Taxes		0			0

NET INCOME ( LOSS)		220,011			(158,106	)

NET INCOME ( LOSS) from continuing Operations		220,011
Less: (Net Income) Loss attributable to non controlling interest in Zander Therapeutics, Inc.		0			48,128

NET INCOME ( LOSS) available to common shareholders		212,311			(109,978	)

BASIC AND DILUTED EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS		0.004			(0.002	)

WEIGHTED AVERAGE NUMBER COMMON SHARES OUTSTANDING		49,170,472			48,976,028

The accompanying Notes are an integral part of these Financial Statements

ENTEST BIOMEDICAL, INC.
Consolidated Statement of Cash Flows
(unaudited)
	Nine Months Ended
	May 31, 2018			May 31, 2017
OPERATING ACTIVITIES
Net (loss)		(1,186,914	)		(440,694	)
Adjustments to reconcile net loss to net cash used by operating activities:
Increase (Decrease) in Additional paid in Capital		0			64,709
increase (Decrease) in Issuance of Stock below Fair Value		0			107,700
Increase (Decrease) in Preferred Stock issued for expenses		0			83,000
Increase (Decrease) in Preferred Stock issued to Consultants					70
Increase (Decrease) Common Stock issued to Consultants					12,720
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses		(117,388	)		(2,996	)
Increase(Decrease) in Unearned Rent		20,000
Increase (Decrease) in Accounts Payable		304,494			(80,661	)
(Increase) Decrease in Accrued Rental Income Receivable		0			(15,000	)
Increase (Decrease) in Accrued Expenses		(85,645	)		(113,827	)
(Increase) Decrease in Accrued Interest Receivable		(132	)		(789	)
(Increase) Decrease in Notes Receivable					(37,449	)
Net Cash Provided (Used) in Operating Activities		(1,065,585	)		(423,217	)
Net Cash Provided (Used) in Investing Activities
Securities Purchased for Cash					(5,000	)
Net Cash Provided (Used) in Investing Activities					(5,000	)
FINANCING ACTIVITIES
Net Cash Provided (Used) in Financing Activities
Common Stock issued for cash					15,000
Common Stock of Subsidiary issued for cash		1,400,000			20,000
Increase (Decrease) in Notes Payable		3,000			424,029
Net Cash Provided by Financing Activities		1,403,000			459,029
Net (Decrease) Increase in Cash		337,415			30,812
Cash at Beginning of Period		86,559			859
Cash at End of Period		423,974			31,671
Supplemental Disclosure of Non Cash Investing and Financing Activities:
Preferred Stock issued for Debt					840,681
The accompanying Notes are an integral part of these Financial Statements

ENTEST GROUP, INC.

(Formerly called ENTEST BIOMEDICAL, INC.)

Consolidated Statement of Comprehensive Income

(Unaudited)

	Quarter Ended November 30
	2018
Net Income (Loss)	$	220,011
Add:
Unrealized Gains on Securities		—
Less:
Unrealized Losses on Securities		—
Comprehensive Income attributable to Non Controlling Interest		—
Total Other Comprehensive Income (Loss)		—
Comprehensive Income	$	220,011

	Quarter Ended November 30,
	2017
Net Income (Loss)	$	(158,106	)
Add:
Unrealized Gains on Securities		43,750
Less:
Unrealized Losses on Securities		—
Comprehensive Income attributable to Non Controlling Interest		—
Total Other Comprehensive Income (Loss)		43,750
Comprehensive Income	$	(114356	)

The accompanying Notes are an integral part of these Financial Statements

~~The Entest~~ENTEST ~~Group~~GROUP,~~Inc~~INC.

(Formerly called ENTEST BIOMEDICAL, INC.)

Consolidated Statement of Cash Flow

(unaudited)

	Quarter Ended November 30, 2018			Quarter Ended 30-Nov-17

OPERATING ACTIVITIES		220,011			(158,106	)
Net Income (loss)
Adjustments to reconcile net loss to net cash used by operating activities:
Increase(Decrease) in stock of subsidiary issued to employees
Increase (Decrease) in stock of subsidiary issued to consultants
Increase (Decrease) in Additional paid in Capital
increase ( Decrease) in Issuance of Stock below Fair Value
increase (Decrease) in Preferred Stock issued for expenses
Increase (Decrease) in Preferred Stock issued to Consultants
(Increase)Decrease in Gain attributable to Deconsolidation
(Increase) Decrease in Gain attributable to disposition of Zander		(188,589	)
Increase (Decrease) Loss attributable to disposition of Entest Biomedical		6,947
(Increase)Decrease Cash Lost in Deconsolidation
Increase (Decrease) in Contributed Capital
(Increase) Decrease in Other Income		(23,629	)
Equity in Losses of Zander
Net Cash Received for divestiture of Entest Biomedical		1,937
Increase (Decrease) Common Stock issued to Consultants
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses
Increase (Decrease) in Unearned Rent		(7,730	)
(Increase) Decrease in Prepaid Expenses					50,608
Increase (Decrease) in Accounts Payable		685			115
(Increase)Decrease in Accrued Rental Income Receivable		(12,000	)		(5,000	)
Increase (Decrease) in Accrued Expenses		495			(39,665	)
(Increase)Decrease in Accrued Interest Receivable
(Increase) Decrease in Notes Receivable

Net Cash Provided (Used) in Operating Activities		(1,873	)		(152,048	)

Net Cash Provided ( Used) in Investing Activities:
Securities Purchased for Cash
Gain on Sale of Securities received prior to deconsolidation

Net Cash Provided ( Used) in Investing Activities:
FINANCING ACTIVITIES
Net Cash Provided (Used) in Financing Activities:
Common Stock issued for cash
Common Stock of Subsidiary issued for cash					900,000
Increase (Decrease) in Notes Payable
Increase (Decrease) Bank Overdraft		(66	)
Increase (Decrease) in Contributed Capital		1,821
Net Cash Provided by Financing Activities		1,755			900,000

Net ( Decrease)Increase in Cash		(118	)		747,952

Cash at Beginning of Period		267			86,559

Cash at End of Period		149			834,510

Supplemental Disclosure of Non CashInvesting and Financing Activities:
Debt Satisfied Through Capital Contribution		19,601

The accompanying Notes are an integral part of these Financial Statements

Entest Group, Inc.

(formerly known as Entest Biomedical, Inc.)

Notes to Consolidated Financial Statements

As of ~~May~~November 3130, 2018

(unaudited)

The accompanying unaudited interim condensed consolidated financial statements of ~~The~~ Entest Group, Inc. (“Entest” or “ the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the United States Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s annual report filed with the SEC on Form 10-K for the year ended August 31, ~~2017~~2018. In general, interim disclosures do not repeat those contained in the annual statements. In the opinion of management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.

NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS

Entest ~~Biomedical~~ Group, Inc (the ~~The~~ “Company”) was incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation. On ~~Until~~ July 1012, 2009, the Company’s ~~principal~~changed ~~business~~its ~~objective~~name ~~was~~to ~~the~~Entest ~~offering~~BioMedical, ofInc. ~~active/leisure~~On ~~fashion~~February ~~design~~12, 2018 the Company ~~clothing~~changed its name from Entest BioMedical, Inc. to Entest Group, Inc.

On Until July 10, 2009, the Company’s principal business objective was the offering of active/leisure fashion design clothing. On July 10, 2009 we abandoned ~~its~~our efforts in the field of active/leisure fashion design clothing ~~when~~and it acquired 100% of the share capital of Entest BioMedical, Inc., a California corporation, (“Entest CA”) from Bio-Matrix Scientific Group, Inc. (“BMSN”) for consideration consisting of 10,000,000 shares of the common stock of the Company and the cancellation of 10,000,000 shares of the Company owned and held by Mr. Rick Plote.

~~On June~~As 18a result of this transaction, ~~2015~~the former stockholder of Entest CA held approximately 70% of the ~~Company~~voting ~~formed~~capital ~~Zander~~stock ~~Therapeutics,~~of ~~Inc~~the Company immediately after the transaction. ~~(“Zander”)~~For ,financial aaccounting ~~Nevada~~purposes, ~~corporation.~~this ~~Zander~~acquisition iswas a ~~58.14%~~reverse ~~owned subsidiary~~acquisition of the Company asby ofEntest ~~May~~CA under 31the purchase method of accounting, ~~2018~~and was treated as a recapitalization with Entest CA as the acquirer.

On ~~February~~June 1218, ~~2018~~2015, the Company ~~changed~~formed ~~its~~Zander ~~name~~Therapeutics, Inc. (“Zander”), a Nevada corporation. Zander was established as a subsidiary of the Company to ~~The~~engage ~~Entest~~primarily ~~Group,~~in ~~Inc~~the development and commercialization of veterinary medical therapies which we intended to license from other entities as well as develop internally.

On May 5, 2018, The Company ~~intends~~declared tothe ~~engage~~distribution ~~primarily~~on a pro rata basis as a dividend in kind of 3,000,000 of the ~~development~~common shares of ~~veterinary~~Zander ~~medical~~Therapeutics, Inc., ~~applications~~par ~~which~~value we$0.0001, ~~intend~~representing toall ~~license~~of ~~from~~the ~~other entities~~shares asof ~~well~~common asstock ~~develop~~owned ~~internally.~~by the Company to:

(a) Holders of record of the outstanding common shares of the Company as of the record date, which was May 30, 2018.

(b) Holders of record of the shares of any outstanding series of the preferred shares of the Company as of the record date, which is May 30, 2018.

Shareholders of the Company received one (1) common share of Zander Therapeutics, Inc. for each 17 common and/or preferred shares of the Company held as of the record date. The distribution of the 3,000,000 common shares of Zander Therapeutics, Inc. to the common and preferred shareholders of the Company occurred on June 11, 2018 (“Distribution Date”).

As a result of the payment of the abovementioned property dividend, the Company’s percentage of ownership of Zander fell below 50% resulting in the deconsolidation of Zander as of the Distribution Date. As of the Distribution Date all assets and liabilities attributable to Zander were derecognized by the Company. The Company recognized a $10,034 gain as a result of the deconsolidation. The property dividend may be deemed to have occurred with a related party as the recipients were shareholders of Entest, including the Chairman and Chief Executive Officer of Entest and Regen Biopharma, Inc. which is a company under common control with Entest.

The Company’s remaining shares of Zander, which consisted of 5,000,000 shares of Zander’s Series M Preferred Stock (“Zander M Stock”) was accounted for under the Equity Method as of the Distribution Date. The Zander M Stock was carried a Fair Value and the carrying value is increased by the Company’s proportionate share of earnings of Zander and decreased by cash dividends paid by Zander as well as the Company’s proportionate share of losses of Zander up to the carrying value. As of August 31, 2018, the carrying value of the Zander M Stock has been decreased by the Company’s proportionate share of the losses of Zander and is 0. On November 16, 2018, the Company and its then Chairman and Chief Executive Officer, David R. Koos, satisfied certain outstanding debt of the Company by transferring all shares of Zander. As of November 30, 2018, the Company no longer owns any equity interest of Zander or Entest CA.

As of January 9, 2019, the Company is a “shell company” as such term is defined in Rule 12(b)(2) promulgated under the Securities and Exchange Act of 1934. This Rule defines as Shell Company as a company that has:

(1) No or nominal operations; and

(2) (i) No or nominal assets;

(ii) Assets consisting solely of cash and cash equivalents; or

(iii) Assets consisting of any amount of cash and cash equivalents and nominal other assets.

The Company’s current business strategy is to acquire an operating company seeking the perceived advantages of being a publicly held corporation. No assurance can be given that such an acquisition shall occur or, if such an acquisition were to occur, it would occur on terms and conditions beneficial to the Company or its shareholders.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. BASIS OF ACCOUNTING

The ~~financial~~ accompanying financial statements have been prepared ~~using~~in ~~the~~accordance ~~basis~~with of accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the accounting and disclosure rules and regulations of the U.S. ~~Under~~Securities and Exchange Commission. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. ~~The~~ The Company has adopted an August 31 fiscal year-end. The Company ~~recognizes~~will recognize revenue from services and product sales when ~~the~~ the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or ~~services~~ services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured.

B. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of Entest CA, ~~the~~a ~~Company’s~~California corporation and wholly owned subsidiary ~~and~~of ~~Zander;~~ the Company’s. ~~majority~~Entest ~~owned~~CA ~~subsidiary~~was disposed of during the quarter ended November 30, 2018. These financial statement also include the accounts of Zander up to June 10, 2018. Significant inter-company transactions have been eliminated.

C. USE OF ESTIMATES

The preparation of financial statements in conformity with ~~generally~~US ~~accepted~~GAAP ~~accounting principles~~ requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and those differences could be material.

D. CASH EQUIVALENTS

~~The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.~~8

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.

E. PROPERTY AND EQUIPMENT

As of ~~May~~November 3130, 2018, the ~~Property~~Company’s property and ~~Equipment~~equipment consists of $0.

F. ~~FAIR~~ ~~VALUE~~INCOME ~~OF FINANCIAL INSTRUMENTS~~TAXES

~~Fair~~The Company accounts ~~value~~for isincome taxes using the ~~price~~liability ~~that~~method ~~would~~prescribed beunder ~~received~~FASB ~~for~~ASC an740, ~~asset~~“Income orTaxes.” Under this method, deferred tax assets and liabilities are determined based on the ~~exit~~difference ~~price~~between the financial reporting and tax bases of assets and liabilities using enacted tax rates that ~~would~~will be ~~paid~~in toeffect ~~transfer~~in athe ~~liability~~year in which the ~~principal~~differences are expected to reverse. The orCompany ~~most~~records ~~advantageous~~a ~~market~~valuation inallowance anto ~~orderly~~offset ~~transaction~~deferred ~~between~~tax ~~market~~assets ~~participants~~if based on the ~~measurement~~weight ~~date. A~~of ~~fair~~available ~~value~~evidence, it is more-likely-than-not ~~hierarchy~~that ~~requires~~some anportion, ~~entity~~or toall, ~~maximize~~of the ~~use~~deferred oftax ~~observable~~assets ~~inputs,~~will ~~where~~not ~~available~~be realized. The ~~following~~effect ~~summarizes~~on ~~the~~deferred ~~three~~taxes ~~levels~~ of ~~inputs~~a ~~required~~change byin ~~the~~tax ~~standard~~rates is ~~that~~recognized as income or loss in the ~~Company~~period ~~uses~~that toincludes ~~measure~~the ~~fair~~enactment ~~value:~~date.

~~Level~~The Company applied ~~1: Quoted~~the ~~prices~~provisions of ASC 740-10-50, “Accounting for Uncertainty in ~~active~~Income ~~markets~~Taxes”, which provides clarification related to the process associated with accounting for ~~identical~~uncertain ~~assets~~tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or ~~liabilities~~the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of November 30, 2018 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s financial instruments as of May 31, 2018 consisted of $ 16,501 of Notes Payable and $8,000 due to TheraCyte, Inc.. The fair value of all of the Company’s financial instruments as of May 31, 2018 were valued according to the Level 3 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company.

The Company has determined that there are no Level 1 or Level 2 inputs for determining the fair value of the Company’s financial instruments. Fair value was determined by the Company utilizing its own assumptions and estimation. There were no transfers between levels for the period presented.

G. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “ Income Taxes. ” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting for Uncertainty in Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of May 31, 2018 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

HG. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "“Earnings Per Share"”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All convertible debt has an anti-dilutive effect on the EPS, therefore Diluted earnings per share are the same as basic earnings per share.

NOTE 3. RECENT ACCOUNTING PRONOUNCEMENTS

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial ~~reporting~~ reporting requirements of companies previously identified as "“Development Stage Entities"” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity'’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted ~~this~~ this standard.

The following accounting standards updates were recently issued and have not yet been adopted by the Company. These standards are currently under review to determine their impact on the Company’s consolidated financial position, results of operations, or cash flows.

In ~~May~~ June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-~~09,~~12 ~~Revenue~~Compensation ~~from~~— ~~Contracts~~Stock ~~with~~Compensation ~~Customers.~~(Topic ~~The~~718), ~~revenue~~Accounting ~~recognition~~for Share-Based Payments When ~~standard~~the ~~affects~~Terms ~~all~~of ~~entities~~an ~~that~~Award ~~have~~Provide ~~contracts~~That ~~with~~a ~~customers,~~Performance ~~except~~Target ~~for~~Could ~~certain~~Be ~~items.~~Achieved ~~The~~after ~~new~~the ~~revenue~~Requisite ~~recognition~~Service ~~standard~~Period. A performance target ~~eliminates~~in ~~the~~a ~~transaction~~share-based payment that affects vesting and ~~industry-specific~~that ~~revenue~~could ~~recognition~~be ~~guidance~~achieved ~~under~~after ~~current~~the ~~GAAP~~requisite ~~and~~service ~~replaces~~period itshould ~~with~~be accounted for as a ~~principle-based~~performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a ~~approach~~result, ~~for~~the ~~determining~~target ~~revenue~~is ~~recognition~~not reflected in the estimation of the award’s grant date fair value. ~~Public~~Compensation ~~entities~~cost ~~are~~would be recognized over the required toservice ~~adopt~~period, if it is probable that the ~~revenue~~performance ~~recognition~~condition ~~standard~~will ~~for~~be ~~reporting~~achieved. The guidance is effective for annual periods beginning after ~~December~~ 15, ~~2016,~~December 2015 and interim ~~and~~periods ~~annual~~within ~~reporting~~those ~~periods~~annual ~~thereafter~~periods. Early adoption is ~~not~~ permitted ~~for public entities~~. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In ~~June~~August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-1215 ~~Compensation~~Preparation —of ~~Stock~~Financial ~~Compensation~~Statements – Going Concern (~~Topic~~Subtopic ~~718~~205-40), ~~Accounting for~~Disclosure ~~Share-Based~~of ~~Payments~~Uncertainties ~~When~~about ~~the~~an ~~Terms~~Entity’s ofAbility anto ~~Award~~Continue ~~Provide~~as ~~That~~a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a ~~Performance~~reporting ~~Target~~entity ~~Could~~as Bea ~~Achieved~~going ~~after~~concern is presumed as the ~~Requisite~~basis ~~Service~~for preparing ~~Period.~~financial Astatements ~~performance~~unless ~~target~~and inuntil athe ~~share-based~~entity’s ~~payment~~liquidation ~~that~~becomes ~~affects~~imminent. ~~vesting~~Preparation ~~and~~of ~~that~~financial ~~could~~statements beunder this ~~achieved~~presumption ~~after~~is commonly referred to as the ~~requisite~~going ~~service~~concern basis of accounting. If and when an entity’s liquidation becomes ~~period~~imminent, financial statements should be ~~accounted~~prepared ~~for~~under asthe aliquidation ~~performance~~basis ~~condition~~of ~~under~~accounting ~~Accounting~~in ~~Standards~~accordance ~~Codification~~with ~~(ASC)~~Subtopic ~~718~~205-30, Presentation ~~Compensation~~of Financial Statements— ~~Stock~~Liquidation ~~Compensation~~Basis of Accounting. AsEven awhen ~~result,~~an ~~the~~entity’s ~~target~~liquidation is not ~~reflected~~imminent, there inmay ~~the~~be ~~estimation~~conditions ofor events that raise substantial doubt about the ~~award'~~entity’s ~~grant~~ability ~~date~~to ~~fair~~continue ~~value.~~as ~~Compensation~~a going concern. ~~cost~~In ~~would~~those situations, financial statements should continue to be ~~recognized~~prepared ~~over~~under the ~~required~~going ~~service~~concern ~~period~~basis of accounting, ifbut itthe amendments isin ~~probable~~this ~~that~~Update ~~the~~should ~~performance~~be ~~condition~~followed ~~will~~to bedetermine ~~achieved~~whether to disclose information about the relevant conditions and events. The ~~guidance~~amendments isin this Update are effective for the annual ~~periods~~period ~~beginning~~ending after 15 December ~~2015~~15, 2016, and ~~interim~~for annual periods ~~within~~and ~~those annual~~ interim periods thereafter. Early ~~adoption~~application is permitted. The Company ~~has~~will ~~reviewed~~evaluate the ~~applicable~~going ~~ASU~~concern ~~and~~considerations ~~has~~in ~~not~~this ASU, however, at the current ~~time~~period, ~~quantified~~management ~~the~~does ~~effects of~~not ~~this~~believe ~~pronouncement,~~that ~~however~~ it ~~believes~~has ~~that~~met ~~there~~the ~~will~~conditions bewhich nowould ~~material~~subject ~~effect~~these ~~on the consolidated~~ financial statements for additional disclosure.

8In January 2017, the FASB issued ASU No. 2017-01, Clarifying the Definition of a Business, which narrows the existing definition of a business and provides a framework for evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or a business. The ASU requires an entity to evaluate if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and activities (collectively, the set) is not a business. To be considered a business, the set would need to include an input and a substantive process that together significantly contribute to the ability to create outputs. The standard also narrows the definition of outputs. The definition of a business affects areas of accounting such as acquisitions, disposals and goodwill. Under the new guidance, fewer acquired sets are expected to be considered businesses. For the Company, this ASU is effective January 1, 2018 on a prospective basis with early adoption permitted. The Company would apply this guidance to applicable transactions after the adoption date.

In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.

NOTE 4. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated net losses of $910,~~965~~036,~~556~~115 during the period from August 22, 2008 (inception) through ~~May~~November 3130, 2018. This condition raises substantial doubt about the Company'’s ability to continue as a going concern. The Company'’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management ~~plans~~ intends to ~~raise~~seek ~~additional~~business ~~funds~~opportunities ~~primarily by offering securities for cash. Management has yet~~ to ~~decide~~review ~~what~~and ~~type~~analyze of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings. During the quarter ended November 30, 2017 Zander Therapeutics, Inc. raised $900,000 through the sale for ~~cash~~purposes of ~~equity~~effecting ~~securities.~~a ~~During the quarter ended February 28~~merger, ~~2018~~acquisition ~~Zander~~or ~~Therapeutics,~~other ~~Inc.~~business ~~raised $500,000~~combination ~~through~~with ~~the~~an ~~sale~~operating ~~for~~company ~~cash of equity securities~~business.

NOTE 5. ~~NOTES~~RELATED ~~PAYABLE~~ PARTY TRANSACTIONS

As of May 31, 2018

Notes Payable:

David Koos ( See Note 6)	$	100
Dunhill Ross Partners, Inc.		850
Blackbriar Partners (See Note 6)		11,000
Regen Biopharma, Inc (See Note 6)		4,551
Total	$	16,501

$1,000 lent to the Company by Blackbriar Partners is due and payable February 17, 2018 and bears simple interest at a rate of 10% per annum

$7,000 lent to the Company by Blackbriar Partners is due and payable February 28, 2018 and bears simple interest at a rate of 10% per annum.

$3,000 lent to the Company by Blackbriar Partners is due and payable May 4, 2019 and bears simple interest at a rate of 10% per annum.

Blackbriar Partners is controlled by David R. Koos , the Company’s sole officer and director.

As of May 31, 2018 the Company remains indebted to David R. Koos , the Company’s sole officer and director, in the principal amount of $100 due and payable in whole or in part at the demand of David Koos and bearing simple interest at a rate of 15% per annum.

Amounts due to Regen Biopharma Inc. as of May 31, 2018 are due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. David R. Koos , the Company’s sole officer, serves as Chairman and Chief Executive officer of Regen Biopharma, Inc. Harry Lander, President and Chief Scientific Officer of Regen Biopharma Inc. serves as President and Chief Scientific Officer of Zander Therapeutics, Inc. The Chief Financial Officer of Regen Biopharma, Inc.is Todd Caven who also serves as Chief Financial Officer of Zander Therapeutics, Inc .

NOTE 6. RELATED PARTY TRANSACTIONS

As of May 31, 2018 the Company remains indebted to Blackbriar Partners in the principal amount of $11,000 of which $1,000 is due and payable February 17, 2018 and bears simple interest at a rate of 10%per annum and of which $7,000 is due and payable February 28, 2018 and bears simple interest at a rate of 10% per annum and of which$3,000 is due and payable May 4, 2019 and bears simple interest at a rate of 10% per annum. Blackbriar Partners is controlled by David R. Koos , the Company’s sole officer and director.

As of May 31, 2018 the Company remains indebted to Regen Biopharma, Inc. in the principal amount of $4,551 due and payable in whole or in part at the demand of the holder and bearing simple interest at a rate of 10% per annum. David R. Koos , the Company’s sole officer, serves as Chairman and Chief Executive officer of Regen Biopharma, Inc. Harry Lander, President and Chief Scientific Officer of Regen Biopharma Inc. serves as President and Chief Scientific Officer of Zander Therapeutics, Inc. The Chief Financial Officer of Regen Biopharma, Inc.is Todd Caven who also serves as Chief Financial Officer of Zander Therapeutics, Inc .

On October 1, 2014 Regen Biopharma Inc. entered into an agreement to sublease approximately 2,320 square feet of office space from the Company. Entest Biomedical Inc. is under common control with Regen Biopharma, Inc. as the Chairman and CEO of the Company also serves as the Chairman and CEO of Regen Biopharma, Inc. The sublease is on a month to month basis and rent payable to the Company by Regen Biopharma Inc is equal to the rent payable to the lessor by the Company and is to be paid in at such time specified in accordance with the original lease agreement between the Company and the lessor. On January 20, 2015 the sublease was amended retroactive to January 1, 2015 as follows:

The rent payable to Entest BioMedical, Inc. by the subtenant is equal to Five Thousand Dollars per month ($5,000) and is to be paid in at such time specified in accordance with the original lease agreement between the Entest BioMedical, Inc. (“Entest”) and the lessor. All charges for utilities connected with premises which are to be paid under the master lease shall be paid by Regen Biopharma, Inc. for the term of this sublease to the extent that such charges exceed the difference between the rent payable to the lessor by Entest under the master lease and the rent payable to Entest by Regen Biopharma, Inc.

On July 3, 2018, Zander ~~June~~entered 23into a sublease agreement with Entest whereby Zander would sublet office space located at 4700 Spring Street, ~~2015~~Suite ~~Regen~~304, La ~~Biopharma~~Mesa, California 91942 from Entest on a month to month basis for $6,000 per month beginning July 5, 2018. On November 16, 2018 Zander Therapeutics Inc. (and ~~“Regen”)~~the ~~entered~~Company ~~into~~agreed anto ~~agreement~~terminate ~~(“Agreement”)~~Zander’s sublease with ~~Zander~~the ~~whereby~~Company effective the rental period ~~Regen~~commencing ~~granted~~November, to2018. ~~Zander~~David anR. ~~exclusive~~Koos, ~~worldwide~~who ~~right~~served as Chairman and ~~license~~Chief ~~for~~Executive ~~the~~Officer ~~development~~of ~~and~~Zander ~~commercialization~~as of ~~certain~~that ~~intellectual~~date also served ~~property~~as ~~controlled~~Chairman byand ~~Regen~~Chief (“Executive ~~License~~Officer ~~IP”)~~of ~~for~~Entest ~~non-human~~as ~~veterinary~~of ~~therapeutic~~that ~~use~~date. ~~for~~Zander awas ~~term~~under common control with Entest as of ~~fifteen~~that ~~years~~date.

~~Pursuant to~~On ~~the~~November ~~Agreement~~16, ~~Zander~~2018, Entest ~~shall~~Group, ~~pay~~Inc. toand ~~Regen~~their ~~one-time,~~Chairman ~~non-refundable~~and Chief Executive Officer, ~~upfront~~David ~~payment~~R. ofKoos, ~~one~~agreed ~~hundred~~to ~~thousand~~satisfy USany ~~dollars~~and ~~($100,000) as~~all aunpaid ~~license~~interest resulting ~~initiation~~from ~~fee~~accrued ~~which~~interest ~~must~~earned beon ~~paid~~Notes ~~within~~Payable 90to ~~days~~Koos ofby ~~June~~Entest ~~23,~~from ~~2015~~the ~~and~~beginning anof ~~annual~~time ~~non-refundable~~to ~~payment~~November of30, ~~one~~2018 ~~hundred~~by transferring ~~thousand~~to USDavid ~~dollars~~R. ~~($100~~Koos 3,000),000 onshares ~~July~~of ~~15th,~~the ~~2016~~Series ~~and~~M ~~each~~Preferred ~~subsequent~~stock ~~anniversary~~ of ~~the~~Zander ~~effective~~Therapeutics, ~~date~~Inc. ofowned by the ~~Agreement~~Company.

~~The~~Entest Group, Inc. ~~abovementioned~~and ~~payments~~Blackbriar ~~may~~Partners be(“BP”) ~~made,~~agreed atto ~~Zander~~satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BP by Entest from the Company’s ~~discretion~~inception to November 30, in2018 ~~cash~~by ortransferring ~~newly~~to ~~issued~~BP ~~common~~20,000 ~~stock~~shares of ~~Zander~~the orSeries M inPreferred ~~common~~ stock of ~~Entest~~Zander ~~BioMedical~~Therapeutics, Inc. ~~valued~~owned asby of the ~~lowest~~Company. ~~closing~~BP ~~price~~is oncontrolled ~~the~~by ~~principal~~David ~~exchange~~Koos, ~~upon~~as ~~which~~of ~~said~~that ~~common~~date, ~~stock~~the ~~trades~~Company’s ~~publicly~~then ~~within~~Chairman ~~the~~and 14Chief ~~trading~~Executive ~~days prior to issuance~~Officer.

~~Pursuant~~Entest Group, Inc. toand the ~~Agreement~~Bio Matrix Scientific Group, ~~Zander~~Inc. ~~shall~~(“BMSN”) ~~pay~~agreed to ~~Regen~~satisfy ~~royalties~~any ~~equal~~and all unpaid interest resulting from accrued interest earned on Notes Payable to ~~four~~BMSN ~~percent~~by ~~(4%)~~Entest offrom the ~~Net~~Company’s ~~Sales~~inception ,to asNovember ~~such~~30, ~~term~~2018 isby ~~defined~~transferring into BMSN 5,000 shares of the ~~Agreement~~Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. As of ~~any~~November ~~Licensed~~16, ~~Products~~2018, asDavid R. ~~such~~Koos ~~term~~was isthe ~~defined~~Chairman inand ~~the~~Chief ~~Agreement,~~Executive inOfficer aof ~~Quarter~~the Company and BMSN.

~~Pursuant to~~Entest ~~the Agreement~~Group, ~~Zander~~Inc. ~~will~~and ~~pay~~ Regen ~~ten~~Biopharma, Inc. ~~percent~~ (~~10%~~“RGBP”) ofagreed ~~all~~to ~~consideration~~satisfy ~~(in~~any ~~the~~and ~~case~~all ofunpaid ~~in-kind~~interest ~~consideration,~~resulting atfrom ~~fair market~~accrued ~~value~~interest asearned ~~monetary~~on ~~consideration)~~Notes ~~received~~Payable to RGBP by ~~Zander~~Entest from ~~sublicensees~~the (beginning ~~excluding~~of ~~royalties~~time ~~from~~to ~~sublicensees~~November ~~based~~30, ~~on Net~~2018 ~~Sales~~by oftransferring ~~any~~to ~~Licensed~~RGBP ~~Products~~250,000 ~~for~~shares ~~which~~of ~~Regen~~the ~~receives~~Series ~~payment~~M ~~pursuant~~Preferred stock toof ~~the~~Zander ~~terms~~Therapeutics, ~~and~~Inc. ~~conditions~~owned ofby the ~~Agreement)~~Company.

~~Zander is~~Entest ~~obligated~~Group, ~~pay~~Inc. toand Regen ~~minimum~~Biopharma, Inc. ~~annual~~(“RGBP”) ~~royalties~~agreed ofto ~~ten~~satisfy ~~thousand~~any USand ~~dollars~~all ~~($10,000)~~rent ~~payable~~prepaid ~~per~~by ~~year~~RGBP onto ~~each~~Entest ~~anniversary~~from the beginning of time to November 30, ~~the~~2018 ~~Effective~~by ~~Date~~transferring ofto ~~this~~RGBP ~~Agreement~~475,000 ~~commencing~~shares onof the ~~second~~Series ~~anniversary~~M Preferred stock of ~~June~~Zander 23Therapeutics, ~~2015~~Inc. ~~This~~owned ~~minimum~~by ~~annual~~the ~~royalty is only~~Company. ~~payable~~As toof ~~the~~November ~~extent~~16, ~~that~~2018, ~~royalty~~David ~~payments~~R. ~~made~~Koos ~~during~~was the ~~preceding~~Chairman ~~12-month~~and ~~period~~Chief doExecutive ~~not~~Officer ~~exceed~~of ~~ten~~the ~~thousand~~Company USand ~~dollars ($10,000)~~RGBP.

~~The~~During the quarter ~~Agreement~~ended ~~may~~November be30, ~~terminated~~2018, the Company divested itself of Entest CA for consideration consisting of $2,000 paid by ~~Regen:~~an entity controlled by the Company’s then Chairman and Chief Executive Officer David R. Koos.

~~If Zander~~The ~~has~~Company ~~not~~recognized a ~~sold~~loss ~~any~~of ~~Licensed~~$6,947 ~~Product~~on bythe ~~ten~~disposition ~~years~~based ofon the ~~effective~~difference ~~date~~between of the ~~Agreement~~Net orAssets ~~Zander~~of ~~has~~the ~~not~~subsidiary ~~sold~~and ~~any~~the ~~Licensed Product~~consideration ~~for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product~~paid.

~~The Agreement~~NOTE may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to Regen with regard to that License IP6. INCOME TAXES

The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to Regen with regard to that License IP is terminated.

As of November 30, 2018
Deferred tax assets:
Net operating tax carry forwards	$	2,110,450
Other		-0-

Gross deferred tax assets		2,110,450
Valuation allowance		(2,110,450)
Net deferred tax assets	$	-0-

The Agreement may be terminated by either party in the event of a material breach by the other party.

On September 28, 2015 the Company issued 8,000,000 of its common shares to Regen in satisfaction of the license initiation fee.

During the quarter ended November 30, 2016 the Company paid $17,000 to Regen as a partial payment of the July 15th, 2016 liability.

On May 30, 2017 the “Company issued 83,000 shares of its Non Voting Convertible Preferred Stock (“ Shares”) to Regen in satisfaction of $83,000 of the July 15th, 2016 liability.

On July 24, 2017 the Company issued 102,852 of its Non Voting Convertible Preferred Stock (“ Shares”) to Regen in satisfaction of $102,852 of liabilities incurred pursuant to the Agreement.

On February 7, 2018 Zander and Regen executed an agreement whereby the June 2018 Anniversary Fee due pursuant to the Agreement would be reduced to $90,000 if paid on or before February 10, 2018

~~On February~~As 8of November 30, 2018 the ~~Zander~~Company ~~paid~~has ~~Regen~~a Deferred Tax Asset of $902,~~000~~110,450 incompletely ~~early~~attributable ~~satisfaction~~to net operating loss carry forwards of ~~the~~approximately ~~June~~$10,049,762 ~~2018~~(which ~~Anniversary~~expire ~~Fee~~20 ~~due~~years ~~pursuant~~from tothe date the ~~Agreement.~~loss was incurred) consisting of:

As of May 31, 2018 there are no outstanding amounts currently due and payable by Zander pursuant to the Agreement.

On February 28, 2016, the Company purchased from a third party 3,500,000 shares of the Series A Preferred stock of Regen Biopharma, Inc for consideration consisting of $5,000 cash and 500,000 shares of the Company’s Series B Preferred Stock.

NOTE 7. INCOME TAXES

	As of May 31, 2018
Deferred tax assets:
Net operating tax carry forwards	$	2,095,633
Other		-0-
Gross deferred tax assets		2,095,633
Valuation allowance		(2,095,633	)
Net deferred tax assets	$	-0-

As of May 31, 2018 the Company has a Deferred Tax Asset of $2,095,633 completely attributable to net operating loss carry forwards of approximately $ 9,979,203(which expire 20 years from the date the loss was incurred) consisting of:

(a) $ 13,647 of Net Operating Loss carry forwards acquired in the reverse acquisition of Entest BioMedical, Inc., a California corporation, and

(b) $ 9 10,~~965~~036,~~556~~115 of Net Operating Loss carry forwards attributable to Entest BioMedical, Inc.

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. In addition, the reverse acquisition in which Entest BioMedical, Inc. was involved in 2009 has resulted in a change of control. Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has recorded a valuation allowance reducing all deferred tax assets to $ -0-.

Income tax is calculated at the 21% Federal Corporate Rate.

NOTE 8 7. ACQUISITION OF ENTEST CA

On July 10, 2009, the Company acquired 100% of Entest CABiomedical, Inc., a California corporation and wholly owned subsidiary of the Company, from ~~BMSN~~ BMSN for consideration consisting of (a) the issuance to BMSN of 10,000,000 newly issued common shares of Entest and (b) the return by Mr. Rick Plote of 10,000,000 shares of Entest’s common stock previously issued to him by Entest for cancellation. During the quarter ended November 30, 2018, the Company divested itself of Entest Biomedical, Inc.

12NOTE 8. ACQUISITION OF THE ASSETS OF PET POINTERS, INC.

~~NOTE~~On January 4, 2011 9Entest CA acquired from Pet Pointers, Inc. ~~ACQUISITION~~, OFa ~~THE~~California ~~ASSETS~~corporation OFdoing ~~PET~~business ~~POINTERS~~as McDonald Animal Hospital (“Seller”), and ~~INC~~Dr. Gregory McDonald DVM (“McDonald”) all the goodwill from McDonald and assets of Seller except cash and accounts receivables used in connection with the operation of a veterinary medical clinic located at 225 S. Milpas Street, Santa Barbara, CA 93103 (the “Business”).

On January 4, 2011 Entest CA acquired from Pet Pointers, Inc., a California corporation doing business as McDonald Animal Hospital (“Seller”), and Dr. Gregory McDonald DVM (“McDonald”) all the goodwill from McDonald and assets of Seller except cash and accounts receivables used in connection with the operation of a veterinary medical clinic located at 225 S. Milpas Street, Santa Barbara, CA 93103 (the "Business").

Consideration for the acquisition consisted of:

I. $70,000 in cash

II. $210,000 of the Company’s common shares valued at the closing price per share as of January 4, 2011

III. Payment of no more than $78,000 to a creditor of the Seller to be paid in monthly installments of $1,500 per month

IV. Payment of no more than $25,000 to additional creditors of the Seller to be paid in monthly installments of $825 per month

V. Payment of $50,000 to McDonald on the first business day of the fourth month following the closing of the acquisition (“Closing”).

NOTE 10 9. DISPOSITION OF THE ASSETS OF PET POINTERS, INC.

On November 28, 2012 the “Company executed an agreement (“Agreement”) with Gregory McDonald ("“McDonald"”), Pet Pointers, Inc. ("“Pet Pointer"”) whereby Mc Donald and Pet Pointer would acquire from the Company all assets (with the exception of cash and accounts receivable) utilized by the Company in the operation of the McDonald Animal Hospital, a full service veterinary clinic owned and operated by the Company and located in Santa Barbara, California (“McDonald Asset Sale”).

On October 10, 2012 a Complaint (“Complaint”) was filed in the Superior Court of the State of California against the Company and David Koos by McDonald, a former employee of the Company, alleging breach of contract and breach of the covenant of good faith and dealing in connection with the assumption of lease obligations by the Company in connection with the acquisition of the assets of Pet Pointers, Inc breach of contract and breach of the covenant of good faith and dealing in connection with an employment agreement enters into with McDonald inc connection with the Acquisition, breach of contract in connection with the Acquisition purchase agreement, breach of the covenant of good faith and dealing in connection with the Acquisition purchase agreement, implied indemnity in connection to amounts owed by McDonald to Anthony and Judi Marinelli, the Internal Revenue Service, and the California Franchise Tax Board, intentional misrepresentation, negligent misrepresentation , failure to pay wages and violations of Sections 2802, 203, and 2806 of the California Labor Code. The Complaint sought judgment for nominal damages, actual damages, compensatory damages, lost wages, compensation, expenses wage benefits and penalties pursuant to California Labor Code Sections 203 et al, 2802 and 2806, indemnification, accrued interest, punitive damages, costs of suit and attorney’s fees.12

AsOn October ~~consideration~~10, to2012 a Complaint (“Complaint”) was filed in the ~~Company~~Superior ~~for~~Court of the ~~assets~~State ~~acquired,~~of California against the Company and David Koos by McDonald, a former employee of the Company, alleging breach of contract and breach of the covenant of good faith and dealing in connection with the assumption of lease obligations by the Company in connection with the acquisition of the assets of Pet Pointers, ~~provided~~Inc tobreach of contract and breach of the ~~Company~~covenant aof ~~General~~good ~~release~~faith ~~whereby~~and dealing in connection with an employment agreement enters into with McDonald ~~and~~inc ~~Pet~~connection ~~Pointer~~with ~~waive~~the Acquisition, ~~release~~breach ~~and~~of ~~discharge~~contract in connection with the ~~Company~~Acquisition purchase agreement, breach of the covenant of good faith and ~~their~~dealing ~~respective~~in ~~assignees~~connection with the Acquisition purchase agreement, ~~officers~~implied indemnity in connection to amounts owed by McDonald to Anthony and Judi Marinelli, ~~directors~~the Internal Revenue Service, ~~shareholders~~and the California Franchise Tax Board, ~~boards,~~intentional ~~owners~~misrepresentation, ~~employees,~~negligent ~~attorneys~~misrepresentation, ~~agents~~failure to pay wages and violations of Sections 2802, ~~trustors~~203, ~~trustees~~and 2806 of the California Labor Code. The Complaint sought judgment for nominal damages, ~~beneficiaries~~actual damages, ~~heirs~~compensatory damages, ~~successors~~lost wages, compensation, expenses wage benefits and ~~representatives~~penalties ~~from~~pursuant ~~all known~~to ~~and~~California ~~unknown~~Labor ~~claims,~~Code ~~demands~~Sections 203 et al, ~~causes~~2802 ofand ~~action~~2806, ~~attorney's~~indemnification, accrued ~~fees~~interest, ~~costs~~punitive damages, orcosts ~~expenses~~of ~~including:~~ suit and attorney’s fees.

As consideration to the Company for the assets acquired, McDonald and Pet Pointers provided to the Company a General release whereby McDonald and Pet Pointer waive, release and discharge the Company and their respective assignees, officers, directors, shareholders, boards, owners, employees, attorneys, agents, trustors, trustees, beneficiaries, heirs, successors, and representatives from all known and unknown claims, demands, causes of action, attorney’s fees, costs, or expenses including:

(1) All claims relating to the Complaint.

(2) Those owed by McDonald to Anthony and Judi Marinelli which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

(3) Those amounts owed by McDonald to the Internal Revenue Service which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

(4) Those amounts owed by McDonald to the California Franchise Tax Board which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

Assets disposed of pursuant to the Agreement include approximately $4,840 of Property Plant and Equipment net of accumulated depreciation as well as all inventory held at the McDonald Animal Hospital.

Assets disposed of pursuant to the Agreement also include

(i) Essentially all intellectual property, including computer software, utilized in connection with the operation of the McDonald Animal Hospital

(ii) All telephone numbers, fax numbers, service marks, trademarks, trade names, fictitious business names, websites, business email addresses, vendor lists, promotional materials, vendor records and any and all business records including, but not limited to, such items stored in computer memories, microfiche, paper record or by any other means relevant to the operation of the McDonald Animal Hospital.

(iii) All customer lists, customer contacts, and any and all customer records that are related to the McDonald Animal Hospital.

As a result of the agreement, the Company recorded a non-cash pre-tax charge for the impairment of goodwill recorded in connection with the acquisition of the McDonald Animal Hospital of approximately $405,000 for the quarter ended November 30, 2012.

Pursuant to to the Agreement, the Company isagrees ~~obligated~~ to ~~make~~waive, ~~payment~~release ofand ~~$13,000~~discharge ~~within~~McDonald ~~five~~and ~~days~~Pet ofPointer ~~the~~from ~~Closing~~all ofknown ~~the~~and ~~Agreement~~unknown asclaims, ~~such~~demands, ~~term~~causes isof ~~defined~~action, inattorney’s ~~the~~fees, ~~Agreement~~costs, or expenses.

Pursuant to the Agreement, the Company agrees to waive, release and discharge McDonald and Pet Pointer from all known and unknown claims, demands, causes of action, attorney's fees, costs, or expenses.13

NOTE 11 10. ~~COMMITMENTS~~DECONSOLIDATION ~~AND~~OF ~~CONTINGENCIES~~ZANDER THERAPEUTICS, INC.

On ~~November~~ 1May 5, ~~2011~~2018, ~~the~~The Company declared ~~entered~~the ~~into~~distribution anon ~~agreement~~a topro ~~lease~~rata ~~approximately~~basis ~~2,320~~as ~~square~~a ~~feet~~dividend in kind of ~~office~~3,000,000 ~~space~~of ~~beginning~~the ~~December 1~~common shares of Zander Therapeutics, ~~2011~~Inc., par ~~for~~value a$0.0001, ~~period~~currently ofowned ~~five~~by ~~years~~Entest Group, Inc. to:

~~Rent to~~(a) beHolders ~~charged~~of torecord of the outstanding common shares of the Company ~~pursuant~~as toof the ~~lease~~record date, which is asMay ~~follows:~~30, 2018.

~~$2,996~~(b) Holders of record of the shares ~~per~~of ~~month~~any ~~for~~outstanding series of the ~~period~~preferred ~~beginning~~shares ~~December~~of 1,the ~~2011~~Company ~~and~~as ~~ending~~of ~~November~~the record date, which is May 30, ~~2012~~2018.

~~$3,116~~Shareholders of the Company ~~per~~shall ~~month~~receive one (1) common share of Zander Therapeutics, Inc. for each 17 common and/or preferred shares of the ~~period~~Company ~~beginning~~held as ~~December~~of 1the record date. The distribution of the 3,000,000 ~~2012~~common shares of Zander Therapeutics, Inc. to the common and ~~ending~~preferred shareholders ~~November~~of 30the Company occurred on June 11, ~~2013~~2018 (“Distribution Date”).

As a result of the payment of the abovementioned property dividend, the Company’s percentage of ownership of Zander fell below 50% resulting in the deconsolidation of Zander as of the Distribution Date. As of the Distribution Date all assets and liabilities attributable to Zander were derecognized by the Company. The Company recognized a $310,~~241~~034gain as a result of the deconsolidation. The Property ~~per~~dividend ~~month~~may ~~for~~be deemed to have occurred with a related party as the ~~period~~recipients ~~beginning~~were ~~December~~shareholders 1of Entest, ~~2013~~including the Chairman and ~~ending~~Chief ~~November~~Executive 30Officer of Entest and Regen Biopharma, ~~2014~~Inc. which is a company under common control with Entest.

$3The Company’s remaining shares of Zander,~~371~~ which consists of 5,000,000 shares of Zander’s Series M Preferred Stock (“Zander M Stock”) ~~per~~was ~~month~~accounted for under the ~~period~~Equity ~~beginning~~Method ~~December~~as 1of the Distribution Date until November 29, ~~2014~~2018. The Zander M Stock is carried a Fair Value and ~~ending~~the ~~November~~carrying 30value is increased by the Company’s proportionate share of earnings of Zander and decreased by cash dividends paid by Zander as well as the Company’s proportionate share of losses of Zander up to the carrying value. As of August 31, ~~2015~~2018, the carrying value of the Zander M Stock has been decreased by the Company’s proportionate share of the losses of Zander and is 0. As of August 31, 2018 Entest beneficially owns 34.82% of the share equity of Zander.

During the quarter ended November 30, 2018, the Company divested itself of the Zander M Stock as satisfaction of $3179,~~506~~318 of interest accrued ~~per~~but ~~month~~unpaid ~~for~~owed by the ~~period~~Company ~~beginning~~and ~~December~~$9,270 1of unearned rental payments made to the Company. As the Zander M Stock had a carrying value of $0, ~~2015~~the ~~and~~Company ~~ending~~recognized ~~November~~a 30gain of $188,589 ~~2016~~on the disposition.

~~On November~~NOTE ~~27,~~11. ~~2016~~DISPOSITION ~~the~~OF ~~lease~~ENTEST ~~was~~BIOMEDICAL, INC., ~~extended~~A ~~until~~CALIFORNIA ~~November 30, 2021~~CORPORATION

~~Rent~~During the quarter toended beNovember ~~charged~~30, to2018 the Company ~~pursuant~~divested toitself of Entest Biomedical, Inc., a California corporation and wholly owned subsidiary, for consideration consisting of $2,000 paid by an entity controlled by the ~~extension~~Company’s isthen Chairman and Chief Executive Officer, David R. Koos, as ~~follows:~~full consideration for Entest Biomedical Inc. as well as any and all furniture, fixtures and equipment owned by the Company which has a carrying amount of $0.

The Company recognized a loss of $26,~~996 per~~947 ~~month~~on ~~for~~the disposition based on the ~~period~~difference ~~beginning~~between ~~December~~the 1,Net ~~2016~~Assets ~~and~~of ~~ending~~the ~~November~~subsidiary ~~30,~~and ~~2017~~the Consideration paid.

$3,116 per month for the period beginning December 1, 2017 and ending November 30, 2018


Cash derecognized in Divestiture				(63)
Accrued Rent Receivable Derecognized in Divestiture				(12000)
Liabilities Derecognized in Divestiture				3116

$3,241 per month for the period beginning December 1, 2018 and ending November 30, 2019

$3,371 per month for the period beginning December 1, 2019 and ending November 30, 2020

$3,506 per month for the period beginning December 1, 2020 and ending November 30, 2021

This property is utilized as office space. The Company believes that the foregoing property is adequate to meet its current needs. While it is anticipated that the Company will require access to laboratory facilities in the future, the Company believes that access to such facilities are available from a variety of sources.

NOTE 12. STOCKHOLDERS EQUITY

Consideration Received in Divestiture		2000
Loss Recognized in Divestiture		(6947)

~~The stockholders'~~ NOTE ~~equity~~12. ~~section~~INVESTMENT ~~of the Company contains the following classes of capital stock as of May 31, 2018:~~SECURITIES

On February 28, 2017 the Company purchased 3,500,000 of the Series A Preferred shares of Regen Biopharma, Inc. for consideration consisting of $5,000 and 500,000 shares of the Company’s Series B Preferred stock.

The Series A Preferred shares of Regen Biopharma, Inc. described above constitute the Company’s sole investment securities as of November 30, 2017. In July 2018, the Series A preferred shares of Regan Biopharma, Inc. was sold by the Company for a total consideration of $35,000. The Company had no investment securities as of the same quarter in 2018.

As of November 30, 2017:

	3,500,000	Series A Preferred shares of Regen Biopharma, Inc

	Basis		Fair Value		Total Unrealized Gains		Net Unrealized Gain or (Loss) realized during the quarter ended November 30, 2017
$	5,000	$	233,800	$	228,800	$	43,750

NOTE 13. STOCKHOLDERS EQUITY

The stockholders’ equity section of the Company contains the following classes of capital stock as of November 30, 2018:

Common Stock:

$0.0001 par value, 500,000,000 shares authorized and 49,170,472 shares issued and outstanding as of ~~May~~November 3130, 2018.

Preferred Stock:

$0.0001 par value 5,000,000 shares authorized of which:

(a) 100,000 are authorized as Series AA Preferred Stock of which ~~634~~667 shares are issued and outstanding as of ~~May~~November 3130, 2018 and (b) 4,400,000 are authorized as Series B Preferred Stock of which 728,073 shares are issued and outstanding as of ~~May~~November 3130, 2018 and (c) 300,000 are authorized as Series AAA Preferred Stock of which 534 shares are issued and outstanding as of ~~May~~November 3130, 2018.

Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series B Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.10 per share of Series B Preferred Stock (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series B Preferred Stock held by them.

If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series B Preferred Stock, then the entire net assets of the Company shall be distributed among the holders of the Series B Preferred Stock, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board..15

If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series B Preferred Stock, then the entire net assets of the Company shall be distributed among the holders of the Series B Preferred Stock, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

Non Voting Convertible Preferred Stock having a $1.00 par value:

3,000,000 ~~shares~~ shares authorized of which 1,001,533 shares are issued and outstanding as of ~~May~~ November 3130 2018 .

Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to the greater of $0.01001 per share or seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.

“CLOSING ~~PRICE"~~ PRICE” shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.

“PRINCIPAL MARKET"” shall mean the principal trading exchange or market for the corporation’s common stock.

“TRADING DAY” shall mean a day on which the Principal Market shall be open for business.

15On October 2, 2018 Entest Group, Inc. (the “Company”) amended Article 4 of the Company’s Articles of Incorporation to change the conversion features of the Company’s Non -Voting Convertible Preferred Stock. The Conversion Price changed from being equal to the greater of $0.01 per share or seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert to being equal to the greater of $0.001 per share or seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.

NOTE 13 14. ~~INVESTMENT~~CHANGE ~~SECURITIES~~OF CONTROL

On ~~February~~November 2815, ~~2017~~2018, David Koos, Regen BioPharma Inc., Bostonia Partners Inc., Sherman Family Trust, Dunhill Ross Partners Inc., Bio-Technology Partners Business Trust (collectively, the ~~Company~~“Sellers”) ~~purchased~~and 3Peiwen Yu (the “Buyer”) entered into a stock purchase agreement (the “SPA”),~~500~~ pursuant to which the Sellers agreed to sell and the Buyer agreed to purchase an aggregate of 23,~~000~~733,334 shares of ~~the~~common stock, 667 shares of Series AAA ~~Preferred~~preferred stock, 534 shares of ~~Regen~~Series ~~Biopharma~~AAA preferred stock and 1,001,533 ~~Inc.for~~shares ~~consideration~~of ~~consisting~~ Non-Voting Preferred Stock of Entest from the Seller for an aggregate purchase price of $5325,000. ~~and~~The ~~500~~closing of the transactions contemplated by the SPA occurred on November 27,~~000~~ ~~shares~~2018. The purchase price was paid out of the ~~Company~~Buyer’s ~~Series~~personal ~~B Preferred stock~~funds.

~~The~~As of the date of the transaction, Entest had 49,170,472 shares of common stock, 728,009 shares of Series AB Preferred Stock, 667 shares of ~~Regen~~Series AA ~~Biopharma~~Preferred Stock, ~~Inc~~534 shares of Series AAA Preferred Stock and 1,001,533 shares of Non-Voting Convertible Preferred Stock outstanding. ~~described~~The ~~above~~securities ~~constitute~~purchased pursuant to the ~~Company’s~~SPA ~~sole~~represent ~~investment~~48.3% ~~securities~~of as the outstanding shares of ~~May~~common 31stock, ~~2018~~90% of the outstanding shares of common stock assuming the conversion of the Non-Voting Convertible Preferred Stock on the execution date of the SPA and 94% of the voting power of Entest.

As contemplated by the SPA, David Koos resigned as Chairman, Chief Executive Officer, President, Acting Chief Financial Officer and Secretary of Entest ~~May~~and 31Peiwen Yu became as a director, Chief Executive Officer and President of Entest, effective November 28, 2018:. Pursuant to the SPA, Mr. Koos will resign as a director of the Company upon compliance by Entest with information statement delivery requirements pursuant to Rule 14f-1 under the Securities Exchange Act of 1934, as amended. Such resignation became effective in November 2018.

	3,500,000		Series A Preferred shares of Regen Biopharma, Inc
	Basis		Fair Value	Total Unrealized Gains in Other Comprehensive Income	Net Unrealized Gain or (Loss) realized during the quarter ended May 31, 2018
$	$5,000	$	$77,700	$72,700	$(65,800)

~~NOTE 14~~ITEM 2. ~~PROPERTY~~MANAGEMENT’S ~~DIVIDEND~~DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

~~On May~~References 5,to ~~2018,~~the ~~The~~ “Company,” “us,” ~~declared~~“our” ~~the~~or ~~distribution~~“we” onrefer ato ~~pro~~Entest ~~rata~~Group, ~~basis~~Inc. asThe afollowing ~~dividend~~discussion inand ~~kind~~analysis of ~~3,000,000~~our financial ofcondition ~~the~~and ~~common~~results ~~shares~~ of ~~Zander~~operations ~~Therapeutics,~~should ~~Inc.,~~be ~~par~~read ~~value~~in ~~$0.0001,~~conjunction ~~currently~~with ~~owned~~our byunaudited ~~Entest~~condensed ~~Group,~~financial ~~Inc.~~statements ~~to:~~and related notes included herein.

~~(a)~~CERTAIN ~~Holders~~FORWARD-LOOKING ofINFORMATION ~~record of the outstanding common shares of the Company as of the record date, which is May 30, 2018.~~

~~(b)~~Information ~~Holders~~provided in ofthis ~~record~~Quarterly ofreport on Form 10Q may contain forward-looking statements within the ~~shares~~meaning of ~~any~~Section ~~outstanding~~21E ~~series~~or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the ~~preferred~~Company’s ~~shares~~expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company’s operations, economic performance, financial conditions, margins and growth in sales of the Company’s products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company’s financial performance and the ~~record~~forward-looking ~~date~~statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission, including ~~which~~the isCompany’s ~~May~~most 30recent Form 10K for the year ended August 31, 2018.

Shareholders of the Company shall receive one (1) common share of Zander Therapeutics, Inc. for each 17 common and/or preferred shares of the Company held as of the record date. The distribution of the 3,000,000 common shares of Zander Therapeutics, Inc. to the common and preferred shareholders of the Company will occur on June 11, 2018 ("Distribution Date"). No fractional shares will be distributed. Where the distribution to the shareholder would result in a fractional share, that distribution will be rounded down to the nearest whole share amount.Overview

~~NOTE~~The Company currently does not have any 15operations and has not actively conducted any operations for the quarter ended November 30, 2018. ~~SUBSEQUENT~~The ~~EVENTS~~Company’s business plan for the next 12 months and beyond such time is to seek new business opportunities or to engage in a business combination with an unidentified company. The analysis of new business opportunities will be undertaken by or under the supervision of the Company’s management. As of the date of this filing, the Company has not entered into any definitive agreement with any party, nor have there been any specific discussions with any potential business combination candidate regarding business opportunities for the Company. There can be no assurance that the Company will be able to identify and acquire any business entity. Even if we successfully acquire a business entity, there is no assurance that we can generate revenue and become profitable.

~~On June~~Results ~~11, 2018 the Company paid out on a pro rata basis as a dividend in kind~~ of ~~3,000,000 of the common shares of Zander Therapeutics, Inc., par value $0.0001, currently owned by Entest Group, Inc. to:~~Operations

~~(a)~~For ~~Holders of record of~~ the ~~outstanding~~three ~~common~~months ~~shares~~ended ofNovember ~~the~~30, ~~Company~~2018 ascompared with of the ~~record~~three ~~date,~~months ~~which~~ended isNovember ~~May~~ 30, ~~2018.~~2017

~~(b)~~The ~~Holders~~Company ofhas ~~record~~not ofconducted any active operations during the ~~shares~~quarter ofended ~~any~~November ~~outstanding~~30, ~~series~~2018. ofNo revenue has been generated by the ~~preferred~~Company ~~shares~~within such period. It is unlikely the Company will have any revenues unless it is able to effect an acquisition or merger with an operating company, of which there can be no assurance. It is management’s assertion that these circumstances may hinder the Company’s ability to continue as a going concern. The Company’s plan of operation for the ~~record~~next ~~date,~~twelve ~~which~~months isshall ~~May~~be ~~30,~~to ~~2018~~locate suitable acquisition candidates.

OnRevenues from continuing operations were ~~June~~$0 15for the quarter ended November 30, 2018 ~~Zander~~and ~~executed~~2017. anNet ~~agreement~~Income from continuing operations was $220,011 for the quarter ended November 30, 2018 while a Net Loss from continuing operations of $158,106 was recognized during the same quarter ended November 30, 2017. Net Income of $220,011 recognized during the quarter ended November 30, 2018 was primarily attributable to ~~sell~~gains 50recognized on the derecognition of $23,~~000~~629 of ~~its~~Aged ~~common~~Payables ~~shares~~as ~~for~~well ~~cash~~as ~~consideration~~recognition of $~~100~~188,~~000~~589 of gain related to settlement of liabilities with the Company’s owned shares of Series M Preferred Stock of Zander Therapeutics, Inc.

~~ITEM~~For the three months ended November 30, 2.2018 ~~MANAGEMENT'S~~and ~~DISCUSSION~~2017, ~~AND~~the ~~ANALYSIS~~Company OFhad ~~FINANCIAL~~operating ~~CONDITION~~expenses ~~AND~~$14,054 ~~RESULTS~~and OF$172,772 ~~OPERATIONS~~comprised of legal, filing, accounting, audit, and other professional service fees incurred in relation to the filing of the Company’s annual and quarterly reports in connection with its reporting obligations as well as rental costs. The Company incurred significantly lowered expenses during the quarter ended November 30, 2018 as compared to the same quarter ended 2017 due to:

~~CERTAIN~~(a) the deconsolidation ~~FORWARD-LOOKING~~of ~~INFORMATION~~ Zander Therapeutics, Inc during the quarter ended August 31, 2018

~~Information provided in this Quarterly report on Form 10Q may contain forward-looking statements within~~ (b) the ~~meaning of Section 21E or Securities~~ ~~Exchange~~elimination ~~Act~~ of ~~1934~~salary that are not historical facts and information. These statements represent the Company's expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company's operations, economic performance, financial conditions, margins and growth in sales of the Company's products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for ~~future periods to differ materially from any forward-looking statement or views expressed herein. The Company's financial performance and~~ the ~~forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the~~ Company ~~with the Securities and Exchange Commission, including the Company'~~’s ~~most recent~~sole ~~Form~~officer ~~10K~~commencing ~~for~~September ~~the year ended August 31~~1, ~~2017~~2018. ~~All references to” We”, “Us”, “Company” or the “Company” refer to Entest Group, Inc and its majority owned subsidiary Zander Therapeutics, Inc.~~

~~As of~~Liquidity ~~May 31, 2018 we had Cash in the amount of $423,974~~ and asCapital ofResources ~~August 31, 2017 we had Cash in the amount of $86,559.\~~

~~The increase~~As ~~in Cash~~ of ~~approximately 389.91%% is primarily attributable to the sale for cash by Zander Therapeutics, Inc. of 900,000 of its common shares for consideration of $900,000 during the quarter ended~~ November 30, ~~2017~~2018, ~~and~~we ~~the~~had ~~sale for~~ cash ~~by Zander~~in ~~Therapeutics,~~the ~~Inc.~~amount of ~~250,000~~$149 ofand ~~its~~as ~~common shares for consideration~~ of ~~$500,000~~August ~~during the quarter ended February 28~~31, 2018 ~~offset by~~we ~~costs~~had ~~incurred~~cash in the ~~operation~~amount of ~~the Company’s business~~$267.

~~As of~~The ~~May~~decrease ~~31, 2018 we had Accrued Interest Receivable~~ in ~~the~~cash ~~amount~~ of ~~$1040~~approximately ~~and~~44.1% is asprimarily ofattributable ~~August~~to ~~31,~~cash ~~2017~~expended ~~we had Accrued Interest Receivable~~ in the ~~amount~~operational activities of ~~$908~~the Company.

~~The~~As of November 30, 2018, we had Current ~~increase~~Portion inof ~~Accrued~~Prepaid ~~Interest~~Expenses ~~Receivable~~of $0 and as of ~~approximately~~August 1431, 2018 we had Current Portion of Prepaid Expenses of $8,000.2% The decrease in Current Portion of Prepaid Expenses is attributable to ~~$132~~the derecognition by the Company of ~~interest~~expenses ~~earned~~prepaid byin connection to an agreement between the Company ~~during~~and Theracyte, Inc. entered into on August 18, 2010 whereby Theracyte would provide up to 25 implantable cell encapsulation devices to the ~~quarter~~Company ~~ended~~solely ~~February~~for ~~28,~~use ~~2018~~by ~~resulting~~the ~~from~~Company in a ~~short~~ten ~~term~~(10) ~~loan~~dog ~~made~~safety study. The amount was derecognized by the Company, when (a) this safety study was abandoned and (b) the ~~principal~~amounts onprepaid ~~such~~are ~~loan~~effectively ~~paid~~uncollectible ~~during~~by the Company due to the ~~quarter~~expiration ~~ended~~of ~~February~~the ~~28,~~statute ~~2018~~of limitations imposed upon such collection activity pursuant to relevant statute.

As of ~~May~~November 3130, 2018 we had ~~Current~~Accounts Payable ~~Portion~~ of ~~Prepaid Expenses of~~ $~~108~~2,~~041~~387 and as of August 31, ~~2017~~2018 we had ~~Current~~Accounts ~~Portion~~Payable of ~~Prepaid Expenses of~~ $5828,~~652~~447.

The ~~increase~~ decrease in ~~Current~~Accounts ~~Portion~~Payable of ~~Prepaid Expenses of 84~~approximately 91.26% is ~~primarily~~ attributable primarily to:

(a) ~~$100,000~~the ofderecognition ~~fees~~by tothe beCompany ~~paid~~during tothe ~~Regen~~quarter ~~Biopharma~~ended November 30, ~~Inc.~~2018 (of an$23,629 ~~entity~~of ~~under~~aged ~~common~~payables ~~control~~which ~~with~~are effectively uncollectible by the ~~Company)~~creditors ~~having~~due ~~been~~to ~~prepaid~~the ~~during~~expiration of the ~~quarter~~statute ~~ended~~of ~~February~~limitations ~~28,~~imposed ~~2018~~upon ~~offset~~such ~~by:~~collection activity pursuant to relevant statute.

(b) the ~~expensing~~derecognition by the Company of $503,~~604~~116 ~~for~~of ~~services~~Payables ~~rendered~~in ~~during~~connection with the ~~quarter~~disposition ~~ended~~of ~~November~~Entest 30Biomedical, ~~2017~~Inc. ~~which~~(a ~~had~~California ~~been~~corporation) ~~prepaid by the Company~~ during the quarter ended ~~August~~November 3130, ~~2017~~2018.

As of ~~May~~November 3130, 2018 3,~~500,000~~ ~~shares~~we ofhad ~~the~~Notes ~~Series~~Payable of A$0 ~~Preferred~~and ~~stock~~as of ~~Regen~~August ~~Biopharma~~31, ~~Inc~~2018, we had Notes Payable of $19,601. ~~owned~~The byreduction usin ~~was~~Notes ~~determined~~Payable byis usattributable to the settlement ~~have~~by athe ~~Fair~~Company ~~Value~~of $19,601 of Notes Payable, $779,~~700~~270 ~~and~~in asUnearned ofRental ~~August~~Income 31and $179,318 ~~2017~~of ~~those~~Interest ~~shares~~Accrued ~~were~~but ~~determined~~Unpaid payment by usthe Company to ~~have~~the arelevant ~~Fair~~creditors ~~Value~~of 5 Million shares of ~~$190~~the Series M Preferred Stock of Zander Therapeutics,~~050~~ Inc.

~~This decrease~~As of ~~59.116~~November %30, is2018 ~~attributable~~we had Amounts Due to anOther ~~unrealized~~of ~~loss~~$0 and as of August 31, 2018, we had Amounts Due to Other of $~~112~~8,~~350~~000. ~~recognized~~The decrease in Due to Other is attributable to the derecognition by the Company ~~with~~of ~~regard~~expenses incurred but unpaid in connection to 3an agreement between the Company and Theracyte,~~500~~ Inc. (“Theracyte”) entered into on August 18,~~000~~ ~~shares~~2010 whereby Theracyte would provide up to 25 implantable cell encapsulation ofdevices to the ~~Series~~Company Asolely ~~Preferred~~for ~~stock~~use ofby ~~Regen~~the ~~Biopharma,~~Company ~~Inc~~in a ten (10) dog safety study. ~~during~~The amount was derecognized by the ~~nine~~Company because ~~months~~(a) ~~ended~~this ~~May~~safety ~~31,~~study ~~2018.~~was ~~Regen~~abandoned ~~Biopharma,~~and ~~Inc.~~(b) isthe ~~under common~~amounts ~~control~~unpaid ~~with~~are effectively uncollectible by Theracyte due to the ~~Company~~expiration of the statute of limitations imposed upon such collection activity pursuant to relevant statute.

As of ~~May~~November 3130, 2018, we had ~~Long Term Portion of Prepaid~~ Accrued Expenses of $683,~~000~~080 and as of August 31, ~~2017~~2018 we had ~~Long~~Accrued ~~Term~~Expenses ~~Portion~~of $181,904. The decrease in Accrued Expenses of approximately ~~Prepaid~~98.3% ~~Expenses~~is attributable primarily to the settlement by the Company of $019,601 of Notes Payable, $9,270 in Unearned Rental Income and $179,318 of Interest Accrued but Unpaid payment by the Company to the relevant creditors of 5 Million shares of the Series M Preferred Stock of Zander Therapeutics, Inc.

~~The increase~~As ~~in Long Term Portion~~ of ~~Prepaid~~November ~~Expenses is attributable to $68~~30,~~000~~ of2018 ~~fees~~we tohad ~~be paid to Regen Biopharma, Inc. ( an~~Unearned ~~entity~~Rental ~~under~~Income ~~common~~of ~~control~~$0 ~~with~~and ~~the~~as ~~Company)~~of ~~having~~August ~~been~~31, ~~prepaid~~2018 ~~during~~we ~~the~~had ~~quarter~~Unearned ~~ended~~Rental ~~February~~Income ~~28,~~of ~~2018~~$17,000.

~~As of~~The ~~May~~decrease ~~31,~~in ~~2018~~Unearned weRental ~~had~~income ~~Accounts~~is attributable ~~Payable of $332,940 and as of August 31, 2017 we had Accounts Payable of $28,446.~~to:

~~The increase~~(a) inthe ~~accounts~~settlement ~~payable~~by ofthe ~~approximately~~Company ~~1070.34%~~of is$19,601 ~~primarily~~of ~~attributable~~Notes toPayable, ~~increases~~$9,270 in ~~Accounts~~Unearned ~~Payable~~Rental byIncome ~~Zander~~and ~~Therapeutics~~$179, ~~Inc.~~318 ~~during~~of Interest Accrued but Unpaid payment by the ~~Quarters~~Company ~~ended~~to ~~February~~the ~~28,~~relevant ~~2018~~creditors ~~and~~of ~~May~~5 31Million shares of the Series M Preferred Stock of Zander Therapeutics, ~~2018~~Inc.

~~As of~~(b) ~~May~~The ~~31,~~recognition ~~2018~~by wethe ~~had~~Company ~~Unearned~~during ~~Rental~~the ~~Income~~quarter ofended ~~$20~~November 30,~~000~~ ~~and~~2018 as of ~~August 31~~$10,000 ~~2017~~of weRental ~~had~~Income ~~Unearned~~previously ~~Rental~~prepaid ~~Income~~by ofRegen $0Biopharma, Inc.

~~The increase~~As inof ~~Unearned~~November ~~Rental~~30, 2018, ~~Income~~we ishad ~~attributable~~$149 tocash ~~rental~~on ~~income~~hand ~~prepaid~~and tocurrent ~~the~~liabilities ~~Company~~of ~~by Regen Biopharma~~$5,467 ~~Inc.~~such ~~for~~liabilities ~~the~~consisting ~~months ended~~of ~~June~~Accounts ,Payable ~~July, August~~ and ~~September~~Accrued ~~of 2018~~Expenses. ~~Regen Biopharma, Inc. is under common control with the Company.~~

AsWe believe that we will not be able to satisfy our cash requirements over the next twelve months. The Company seeks to acquire an operating company seeking the perceived advantages of ~~May~~being 31a publicly held corporation. No assurance can be given that such an acquisition shall occur or, ~~2018~~if wesuch ~~had~~an ~~Accrued~~acquisition ~~Expenses~~were ofto ~~$183~~occur,~~755~~ it would occur on terms and asconditions beneficial to the Company or its shareholders. The Company is also dependent upon the receipt of ~~August~~capital ~~31,~~investment ~~2017~~or weother ~~had~~financing ~~Accrued~~to ~~Expenses~~fund its ongoing operations and to execute its business plan of ~~$269~~seeking a combination with a private operating company. [In addition,~~398~~ the Company anticipates that it will be dependent upon certain related parties to provide continued funding and capital resources.] If continued funding and capital resources are unavailable at reasonable terms, the Company may not be able to implement its plan of operations.

~~The decrease~~Critical inAccounting ~~Accrued~~Policies ~~Expenses~~and ~~of approximately 31.7% is attributable to~~Estimates

~~(a)~~Use ~~the payment to David R. Koos~~ of ~~$40,000 of previously accrued salary during the quarter ended November 30, 2017 offset by the accrual of $334 of interest expenses incurred during the quarter ended November 30, 2017~~Estimates

~~(b)~~The ~~the~~preparation ~~payment~~of financial tostatements ~~David~~in R.conformity ~~Koos~~with ofaccounting ~~$40,000~~principles generally accepted in the United States of ~~previously~~America ~~accrued~~requires ~~salary~~management to ~~during~~make estimates and assumptions that affect the ~~quarter~~reported ~~ended~~amounts ~~February~~of ~~28,~~assets ~~2018~~and ~~offset~~liabilities byand ~~the~~disclosure ~~accrual~~of contingent liabilities at dates of ~~$330~~the financial statements and the reported amounts of ~~interest~~revenue and expenses ~~incurred~~ during the ~~quarter~~periods. ~~ended~~Actual ~~February~~results 28could differ from these estimates. Our significant estimates and assumptions include depreciation, ~~2018~~stock-based compensation and the valuation allowance relating to the Company’s deferred tax assets.

~~(c)~~Recently ~~the~~Issued ~~payment~~Accounting to David R. Koos of $8,000 of previously accrued salary during the quarter ended May 31, 2018 offset by (i) the accrual of $361 of interest expenses incurred during the quarter ended May 31, 2018 and (ii) the accrual of $1,330 of employment related taxes incurred during the quarter ended May 31, 2018.Pronouncements

AsReference is made to ofthe ~~May~~“Recent 31Accounting Pronouncements” in Note 2 to the Financial Statements included in this report for information related to new accounting pronouncement, ~~2018~~none weof which had ~~Notes~~a ~~Payable~~material ofimpact ~~$16~~on our consolidated financial statements,~~501~~ and asthe future adoption of ~~August~~recently 31issued accounting pronouncements, ~~2017~~which we ~~had~~do ~~Notes~~not ~~Payable~~expect ofwill ~~$13,501~~have a material impact on our consolidated financial statements.

~~The increase~~Off-Balance inSheet ~~Notes Payable of approximately 22.2% is attributable to $3,000 of additional indebtedness incurred by us during the quarter ended May 31, 2018.~~Arrangements

As of ~~May~~November 3130, 2018 ~~we had a Property Dividend Payable of $57~~,~~143~~ ~~and as of August 31, 2017~~ we ~~had~~do anot ~~Property~~have ~~Dividend~~any ~~Payable~~off-balance ~~of $0~~sheet arrangements.

The Property Dividend Payable is attributable to the declaration during the quarter ended May 31, 2018 by the Board of Directors of the Company of the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., par value $0.0001, currently owned by Entest Group, Inc. to:19

~~(a)~~Item ~~Holders~~3. ofQuantitative ~~record~~and ofQualitative ~~the~~Disclosures ~~outstanding~~About ~~common~~Market ~~shares of the Company as of the record date, which is May 30, 2018.~~Risk

~~(b)~~We ~~Holders~~are ofa ~~record~~smaller ofreporting company ~~the~~as ~~shares~~defined ofby ~~any~~Rule ~~outstanding~~12b-2 ~~series~~ of the ~~preferred~~Securities ~~shares~~Exchange Act of ~~the~~1934 ~~Company~~and asare ofnot required to provide the ~~record~~information ~~date~~under this item. We have chosen to disclose, ~~which~~however, isthat ~~May~~we 30have not engaged in any transactions, ~~2018~~issued or bought any financial instruments or entered into any contracts that are required to be disclosed in response to this item.

19Item 4. Controls and Procedures.

~~Material Changes~~Evaluation inof ~~Results~~Disclosure ofControls ~~Operations~~and Procedure.

~~Revenues from~~Pursuant ~~continuing~~to ~~operations~~Rule ~~were~~13a-15(b) under $0the ~~for~~Exchange Act, the ~~three~~Company ~~months~~carried ~~ended~~out ~~May~~an 31evaluation, ~~2018~~under the supervision and ~~-0-~~with ~~for~~the participation of Peiwen Yu, who is the ~~three~~Company’s ~~months~~Principal ~~ended~~Executive ~~May~~Officer/Principal 31Financial Officer, ~~2017~~of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. ~~Net~~ The Company’s disclosure controls and procedures are designed ~~Losses~~to ~~from~~provide ~~continuing~~a ~~operations~~reasonable ~~were~~level ~~$619,000~~of ~~for~~assurance of achieving the ~~three~~Company’s ~~months~~disclosure ~~ended~~control ~~May~~objectives. ~~31,~~The ~~2018~~Company’s Principal ~~and~~Executive ~~$90,189~~Officer/Principal ~~for~~Financial Officer has concluded that the ~~same~~Company’s ~~period~~disclosure ~~ended~~controls and procedures ~~2017~~are not effective at this reasonable assurance level as of the period covered.

~~The increase~~Changes in ~~Net~~Internal ~~Losses~~Controls ~~from~~over ~~continuing operations of approximately 586.33% is primarily attributable to increases in expenses~~Financial attributable to Research and Development, General and Administrative ,Rent and Consulting recognized during the quarter ended May 31, 2018 when compared to the same quarter ended 2017 as well as $11,605 in Other income recognized during the quarter ended May 31, 2017.Reporting

~~Revenues~~In connection with ~~from~~the ~~continuing~~evaluation ~~operations~~of ~~were~~the $0Company’s ~~for~~internal controls during the ~~nine~~period ~~months~~commencing ~~ended~~on ~~May~~September 311, 2018 and ~~-0-~~ending ~~for~~on November 30, 2018, Peiwen Yu, who is both the ~~nine~~Company’s ~~months~~Principal ~~ended~~Executive ~~May~~Officer ~~31,~~and ~~2017. Net Losses~~Principal ~~from~~Financial ~~continuing~~Officer ~~operations~~has determined that there were ~~$1,186,914~~no ~~for~~changes to the ~~nine~~Company’s ~~months~~internal ~~ended~~controls ~~May~~over ~~31,~~financial ~~2018~~reporting ~~and~~that ~~$440~~have been materially affected,~~694~~ or ~~for~~is reasonably likely to materially effect, the ~~same~~Company’s ~~period~~internal ~~ended 2017~~controls over financial reporting.

~~The increase~~PART inII ~~Net~~- ~~Losses~~OTHER from continuing operations of approximately 169.3% is primarily attributable to increases in expenses attributable to Research and Development and Consulting recognized during the nine months ended May 31, 2018 when compared to the same period ended 2017 as well as $76,697 in Other income recognized during the nine months ended May 31, 2017 offset by:INFORMATION

~~(a)~~Item ~~lower~~1. ~~General~~Legal ~~and Administrative Expenses recognized during the nine months ended May 31, 2018 when compared to the same nine months ended 2017~~Proceedings.

~~(b) lower interest expense recognized during the nine months ended May 31, 2018 when compared to the same nine months ended 2017~~None.

~~(c)~~Item ~~the~~1A. ~~recognition~~Risk ~~during the quarter ended February 28, 2017 of 107,700 of expense attributable to Issuance of Securities for less than Fair Value~~Factors.

~~As of~~We ~~May~~are ~~31,~~a ~~2018~~smaller wereporting ~~had~~company ~~$423,974~~as ~~cash~~defined by onRule ~~hand~~12b-2 ~~and current liabilities~~ of ~~$618,339~~the ~~such~~Securities ~~liabilities~~Exchange ~~consisting~~Act of ~~Accounts~~1934 ~~Payable, Notes Payable, Amounts due to Others, Property Dividend Payable~~ and ~~Accrued~~are ~~Expenses.~~not Werequired ~~feel we will be able~~ to ~~satisfy~~provide ~~our cash requirements over~~ the ~~next~~information ~~twelve~~under ~~months~~this ~~and intend to seek additional financing~~item.

~~We currently~~Item ~~plan~~2. toUnregistered ~~raise~~Sales ~~additional~~of ~~funds~~Equity ~~primarily~~Securities byand ~~offering~~Use ~~securities~~of ~~for cash.~~Proceeds

~~There is no guarantee that we will be able to raise any capital through any type of offerings~~None. We cannot assure that we will be successful in obtaining additional financing necessary to implement our business plan. We have not received any commitment or expression of interest from any financing source that has given us any assurance that we will obtain the amount of additional financing in the future that we currently anticipate. For these and other reasons, we are not able to assure that we will obtain any additional financing or, if we are successful, that we can obtain any such financing on terms that may be reasonable in light of our current circumstances.

~~As of~~Item ~~June~~3. ~~22,~~Defaults ~~2018~~Upon weSenior ~~are not party to any binding agreements which would commit Entest to any material capital expenditures.~~Securities

20None.

Item 3 4. ~~Quantitative~~Mine ~~and~~Safety ~~Qualitative~~ Disclosures ~~About Market Risk~~

~~As a~~Not ~~smaller reporting company, as defined by Rule 229~~applicable.10(f) (1) of Regulation S-K, we are not required to provide the information required by this Item. We have chosen to disclose, however, that we have not engaged in any transactions, issued or bought any financial instruments or entered into any contracts that are required to be disclosed in response to this item.

Item 4 5. ~~Controls~~Other ~~and Procedures.~~Information

~~Evaluation of Disclosure Controls and Procedure~~None.

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is the Company's Principal Executive Officer/Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. The Company's disclosure controls and procedures are designed to provide a reasonable level of assurance of achieving the Company's disclosure control objectives. The Company's Principal Executive Officer/Principal Financial Officer has concluded that the Company's disclosure controls and procedures are, in fact, effective at this reasonable assurance level as of the period covered.20

~~Changes in~~Item ~~Internal~~6. ~~Controls over Financial Reporting~~Exhibits

~~In connection~~(a) ~~with~~Exhibits ~~the~~required ~~evaluation~~by ofItem ~~the~~601 ~~Company's~~of ~~internal~~Regulation controls during the period commencing on March 1, 2018 and ending on May 31, 2018, David Koos, who is both the Company's Principal Executive Officer and Principal Financial Officer has determined that there were no changes to the Company's internal controls over financial reporting that have been materially affected, or is reasonably likely to materially effect, the Company's internal controls over financial reportingS-K.

PART II - OTHER INFORMATION

Exhibit		Description

31.1		Certification of the Company’s Principal Executive Officer and Principal Financial and Accounting Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended November 30, 2018.

32.1		Certification of the Company’s Principal Executive Officer and Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB		XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

~~Item 1. Legal Proceedings.~~ SIGNATURE

~~None~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

		ENTEST GROUP, INC.

Dated: January 22, 2019	By:	/s/ Peiwen Yu
		Peiwen Yu
	Title:	Chief Executive Officer and President (Principal Executive officer, and Principal Financial and Accounting Officer)

~~Common Shares of Zander Therapeutics Inc.~~21

On June 15 2018, Zander Zander executed an agreement to sell 50,000 of its common shares (“Shares”) for cash consideration of $100,000.

The Shares were sold pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend is to be placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Reserved

None.

Item 5. Other Information

None.

Item 6. Exhibits

31	Certification of Chief Executive Officer
32	Certification of Chief Financial Officer
10.1	Securities Purchase Agreement

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ENTEST BIOMEDICAL, INC.
	By:	/s/ David R. Koos
		David R. Koos
		Chief Executive Officer
	Dated:	June 22, 2018

Filing Compare · ENTEST GROUP, INC.